Compare GSK plc (GSK) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Las Vegas Sands Corp. — how do they compare? GSK plc trades at $52.74 (market cap $101.34B), while Las Vegas Sands Corp. trades at $45.64 (market cap $29.68B). The key difference: GSK plc is far larger — about 3.4× Las Vegas Sands Corp.'s market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | LVS | |
|---|---|---|
Market Cap | $101.34B | $29.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $69.49 |
52-Week Low | $36.20 | $44.78 |
Enterprise Value | $121.95B | $42.07B |
Dividend Yield | 3.49% | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
LVS trades at $45.40, up 1.38% with strong earnings beats in recent quarters. Technical indicators show bearish momentum despite oversold RSI levels near support at $44. Fundamentally, revenue grew to $13.02B in 2025 with net income of $1.63B, though debt levels remain elevated at 73.15% of assets. Recent news highlights ESG achievements and Macao expansion efforts.
Analyst consensus is bullish with a $65.40 price target (61% buy ratings), but high leverage and bearish technical signals pose near-term risks. Upside depends on sustained gaming recovery and debt management, while macroeconomic pressures could challenge growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
